活化凝血时间与抗活化因子X活性监测主动脉瘤血管内手术中普通肝素治疗的比较
该回顾性研究纳入104例接受血管内手术的主动脉瘤患者,比较活化凝血时间(ACT)与抗活化因子X(anti-Xa)活性监测普通肝素(UFH)治疗的相关性及与围术期出血的关联。结果显示ACT与anti-Xa相关性弱(rs=0.46),仅31%患者ACT≥250秒而全部患者anti-Xa≥0.5 IU/mL;峰值ACT≥250秒与出血无关,峰值anti-Xa≥1.2 IU/mL独立与出血相关(OR 4.95)。
要点
- ACT与anti-Xa监测UFH相关性弱(rs=0.46,P<.001)。
- 峰值ACT≥250秒与围术期出血无关(OR 1.05,95%CI 0.41-2.70,P=.952)。
- 峰值anti-Xa≥1.2 IU/mL独立与围术期出血相关(OR 4.95,95%CI 1.82-13.48,P=.002)。
核心结论
- 在主动脉瘤血管内手术患者中,ACT与anti-Xa测量相关性差;仅峰值anti-Xa活性升高独立与围术期出血相关,而ACT升高无关。
- 作者认为,主动脉支架术中采用anti-Xa监测UFH治疗可能减少UFH总用量;作者进一步推测该方法可能减少围术期出血。
研究设计与样本
- 回顾性研究,纳入104例接受血管内手术的主动脉瘤患者,进行重复凝血测量。
- 临床常规根据ACT(目标范围≥250秒)追加UFH剂量,每次ACT测量时平行测定anti-Xa活性;UFH追加仅基于ACT测量。
- 围术期出血定义为血红蛋白下降≥3 g/dL或24小时内输注红细胞。
主要发现
- 初始UFH推注(中位数67 IU/kg体重)后,ACT与anti-Xa测量呈弱相关(rs=0.46;P<.001)。
- ACT中位数233秒(范围127-374秒;四分位距204-257秒);anti-Xa活性中位数1.0 IU/mL(范围0.5-2.0 IU/mL;四分位距0.9-1.2 IU/mL)。
- 仅31%的患者ACT值≥250秒,而全部患者anti-Xa活性≥0.5 IU/mL;因此ACT频繁触发UFH追加。
- 术中UFH总用量中位数90 IU/kg,峰值ACT中位数255秒(四分位距234-273秒),峰值anti-Xa活性中位数1.2 IU/mL(四分位距1.0-1.4 IU/mL)。
- 围术期出血发生于40例(38%)患者;峰值ACT≥250秒与出血无关(比值比1.05;95%置信区间0.41-2.70;P=.952),而峰值anti-Xa活性≥1.2 IU/mL独立与出血相关(比值比4.95;95%置信区间1.82-13.48;P=.002);此外,未发生围术期血栓栓塞事件。
临床怎么用
- 作者认为,主动脉支架术中采用anti-Xa监测UFH治疗可能减少UFH总用量。
- 作者进一步推测,该方法可能减少围术期出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend administration of unfractionated heparin (UFH) and measurement of activated clotting time (ACT) during endovascular procedures. The aim of this study was to compare ACT and anti-activated factor X (anti-Xa) measurements for monitoring of UFH therapy during an aortic endograft procedure and to assess the association of peak ACT and peak anti-Xa activity with periprocedural bleeding. METHODS: We retrospectively studied 104 patients with aortic aneurysm undergoing endovascular procedures with repeated coagulation measurements. After a UFH bolus, further UFH doses were given according to ACT (target range, ≥250 seconds) in clinical routine, and in parallel to each ACT (Hemochron; Accriva Diagnostics, Newport Beach, Calif) measurement, we determined anti-Xa activity (HemosIL Liquid anti-Xa; Instrumentation Laboratory, Bedford, Mass). UFH redosing was solely based on the ACT measurements. We defined periprocedural bleeding as a drop in hemoglobin level ≥3 g/dL or red blood cell transfusion within 24 hours. RESULTS: After the initial UFH bolus (median, 67 IU/kg body weight), ACT and anti-Xa measurements showed a weak correlation (rs, 0.46; P < .001). Median ACT was 233 seconds (range, 127-374 seconds; interquartile range [IQR], 204-257 seconds); median anti-Xa activity was 1.0 IU/mL (range, 0.5-2.0 IU/mL; IQR, 0.9-1.2 IU/mL). Only 31% of the patients had an ACT value ≥250 seconds, whereas all patients had an anti-Xa activity ≥0.5 IU/mL. Accordingly, ACT triggered redosing of UFH frequently. Consequently, we saw a median total UFH use of 90 IU/kg during the procedure, a median peak ACT of 255 seconds (IQR, 234-273 seconds), and a median peak anti-Xa activity of 1.2 IU/mL (IQR, 1.0-1.4 IU/mL). Periprocedural bleeding occurred in 40 (38%) patients. Peak ACT ≥250 seconds was not associated with bleeding (odds ratio, 1.05; 95% confidence interval, 0.41-2.70; P = .952), whereas peak anti-Xa activity ≥1.2 IU/mL was independently associated with bleeding (odds ratio, 4.95; 95% confidence interval, 1.82-13.48; P = .002). Moreover, no periprocedural thromboembolic event occurred. CONCLUSIONS: In this retrospective study of patients with aortic aneurysm undergoing an endovascular procedure, ACT and anti-Xa measurements showed poor correlation; only increased peak anti-Xa activity was independently associated with periprocedural bleeding, not increased ACT. Our findings also suggest that monitoring of UFH therapy with anti-Xa during aortic endograft procedures may reduce total UFH use. We further speculate that this approach could reduce periprocedural bleeding.
引用
- Dieplinger B, Egger M, Luft C, et al. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure. J Vasc Surg. 2018. PMID: 29571622. doi:10.1016/j.jvs.2017.11.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。